Showing 1 - 4 results of 4 for search 'Glenwood D. Goss', query time: 0.03s Refine Results
  1. 1
    Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic

    Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic by Glenwood D. Goss, Johanna N. Spaans, David Huntsman, Timothy Asmis, Natalie M. Andrews Wright, Marc Duciaume, Pardeep Kaurah, Ruth R. Miller, Shantanu Banerji, Harmanjatinder S. Sekhon, Marcio M. Gomes

    Published 2022-04-01
    Get full text
    Article
  2. 2
    Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

    Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer. by Grant A Howe, Bin Xiao, Huijun Zhao, Khalid N Al-Zahrani, Mohamed S Hasim, James Villeneuve, Harmanjatinder S Sekhon, Glenwood D Goss, Luc A Sabourin, Jim Dimitroulakos, Christina L Addison

    Published 2016-01-01
    Get full text
    Article
  3. 3
    Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

    Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial by Glenwood D. Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young J. Min, Andrea Ardizzoni, Shaun Bender, Agnieszka Cseh, Enriqueta Felip

    Published 2021-07-01
    Get full text
    Article
  4. 4
    Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

    Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial by Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Z Guclu, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Shirish M Gadgeel, Bushi Wang, Vikram K Chand, Glenwood D Goss

    Published 2015-09-01
    Get full text
    Article

Search Tools: